Australia-based startup Synchron has implanted a fifth brain computer device and the first device in the brains of patients in the United States. It has emerged as a potential rival to Neuralink of Elon Musk, CEO of Tesla Inc, which has not yet received regulatory approval.
On July 6, doctors at Mount Sinai West Medical Center in New York transplanted Syncron’s first 1.5-inch device into the brain of an ALS (Amyotrophic Lateral Sclerosis) patient, according to Bloomberg.
After recovery, patients who are unable to move or talk are expected to be able to surf the Internet and communicate by email or text just by thinking.
The implant is made up of wires and electrodes that doctors implant in the blood vessels of the patient’s brain and translate his thoughts into commands sent to the computer.
The email sent by Benzinga to Synchron for comment did not elicit any response at the time of the press.
Synchron has already transplanted the device to four Australian patients who were able to perform tasks such as sending WhatsApp messages and purchasing online without side effects.
This was the first step the company took in the United States and was ahead of competitors such as Mask’s Neuralink, which develops microchips that read and stimulate brain function.
Last year, Synchron was approved by the US Food and Drug Administration (FDA) to begin trials in patients with severe paralysis.
On the other hand, the mask Neuralink has not yet been approved by the FDA. He said in 2021 that his company plans to start porting computer chips to humans this year.
By Navdeep Yadav
© 2022 Benginga.com. Benzinga does not provide investment advice. all rights reserved.